Epidemiology
The prevalence of multidrug-resistant Enterobacteriaceae has steadily increased in recent years and varies by geographic region. According to the National Nosocomial Infections Surveillance System, 20.3% of K. pneumoniae isolates from US intensive care units in 2003 were third-generation cephalosporin nonsusceptible, representing a 47% increase from the previous 5 year period? The MYS-TIC (Meropenem Yearly Susceptibility Test Information Collection) Program, a global antibiotic surveillance program, documented a fivefold increase in the prevalence of ESBL-producing E. coli between 1997 and 2004 in Europe. In contrast, the prevalence in the US decreased from 5.1% to 1.4%.8 Almost 14% of all Klebsiella spp. in Europe were ESBL-producing in 2004, compared with 4.4% in the US. The lack of simple and reliable testing results in incomplete knowledge of the exact prevalence of AmpCmediated resistance. However, acquired AmpC resistance has been detected in 49% of E. coli and 55% of Klebsiella isolates, with known preexisting ceftazidime resistance submitted to a United Kingdom reference lab," In the US, 8 .5-11 % of ceftazidime-resistant K. pneumoniae have been found to produce AmpC f3-lactamases. I O ,l1
Characterization of Extended-Spectrum and AmpC fl-Iactamases

EXTENDED-SPECTRUM~LACTAMASES
The most commonly observed extended-spectrum and AmpC f3-1actamases are listed in Table 1 ,12,13 ESBLs are plasmid-mediated and confer broad-spectrum resistance to third-generation cephalosporins, f3-lactamase inhibitor combinations, and aztreonam. These mobile genetic elements also frequently carry the genes encoding resistance to aminoglycosides, fluoroquinolones, and trimethoprim/ sUlfamethoxazole. The majority of ESBLs are derived from TEM-l, TEM-2, and SHV-l~-Iactamases. Termed Class A~-Iactamases, TEM-l and SHV-l have the ability tohydrolyze aminopenicillins (amoxicillin and ampicillin), Carboxypenicillins (ticarcillin), ureidopenicillins (piperacillin), and earlygeneration cephalosporins. To date,more than 130 TEM enzymes and more than 50 SHY enzymes have beenclassifiedPMutations in these~-l actamases have resulted in the evolution of ESBLsand conferadditional resistance to third-generation cephalosporins and aztreonam. TEM-and SHY-type ESBLs generally are unableto break down the /3-lactam structure of the cephamycins (eg,cefotetan, cefoxitin, and cefmetazole) or the carbapenems (eg, imipenem, meropenem, ertapenem). However, theyare generally susceptible to~-l actamase inhibitors suchas clavulanic acid, sulbactam, and tazobactam. TEM-and SHY-type ES-BLsaremostcommonly observed in E. coli,K.pneumoniae, P. tnirabilis, andotherEnterobacteriaceae.
The secondmost commongroup of ESBLs is the crx-M~-l actamases, so namedfor theirability to hydrolyze cefotaxirne and, to a lesserextent,ceftazidime. crX-M-type enzymes are most commonly found in Salmonella enterica and E. coli, although they have also been described in P. mirabilis,Enterobactercloacae, and Enterobacteraero-Benesw OXA-typeenzymes are anotherimportantfamily of ESBLs. In contrast to the TEM, SHY,and CTX-M en-zYmes, OXA-typeESBLs belongto molecular class D and are found primarilyin Pseudomonas aeruginosa and only rarely in Enterobacteriaceae." OXA-type ESBLs confer resistance to ampicillin and cloxacillin and, unlike other EsBLs, are poorlyinhibited by clavulanic acid.'! AMPC fJ-LACTAMASES UnlikeESBLs, the majority of AmpC~-l actamases are chromosomally mediated and are found in P. aeruginosa, E. cloacae, E. aerogenes, Citrobacter freundii, Serratia marcescens, and Morganella morganii. Bacteriapossessing AmpC~-l actamases are resistant to penicillins and cephalosporins, including the cephamycins, and~-l actamase inhibitors. This lackof inhibition'by cephamycins and~-l ac tamase inhibitors differentiate ESBLsfrom AmpC /3-lactamases. Expression of chromosomally mediated AmpC/3-lactamases usually occurs at lowlevels in a "repressed" state.
Two mechanisms can lead to constitutive~-l actamase production. Is The first is the induction of~-l actamase production in the presence of certain~-l actam antibiotics. Potent inducers include cefoxitin, clavulanic acid,andirnipenem, although all cephalosporins can induceenzymeproduction to SOme degree," Comparedwith imipenem, meropenemexhibits a lower~-l actamase induction potential," There is littleknown regarding theinduction potential of ertapenem. Although imipenem is a potentinducer, it remains stable in the presence of increased AmpC production, distinguishing this drug from other~-l actams.
Another mechanism for expressionof constitutive /3-lactamase production is the selection of derepressed mutants. Mutations in the ampD permease gene coding foran enzymatic repressor of AmpCcanleadto highlevel constitutive production of /3-lactamase in the absence of any antibiotic inducer,"
Of recent concern is the developmentof plasmid-mediated AmpC~-l actamases.
The ability of AmpC to be encodedon highly mobile plasmids can lead to dissemination of antibiotic resistance to diverse bacterial populations. Since their discovery in the late 1980s,plasmid-mediated AmPC /3-lactamases have been describedin organisms not normally harboring a chromosomal AmpC gene. These bacteria include Salmonella spp., Klebsiella spp., E. coli, and P.mirabilis.Unlike chromosomallymediated AmpC 
Challenges Associated with Laboratory Detection
Timelyand accurate identification of the causative pathogen is essential in the selection of the most appropriate antibiotic treatment.Unfortunately, ESBL-mediated resistance is not always detectable using routine antibiotic susceptibility tests. All clinically significant isolates of E. coli and K. pneumoniae, including those associated with bacteremia, should undergo screening for ESBL production, with additional confirmatory testing." In the above case, screening and confirmatory testing should have taken place with the initial isolation of the organism.The intermediate in vitro susceptibility to ceftazidime(particularly in the presence of "susceptibility"to other penicillinsand broad-spectrumcephalosporins) also raises the suspicion that the organism mightbe an ESBL producer.
Many laboratory tests have been developed for the detection of ESBLs (Table2).20 These tests include doubledisk diffusion, microdilution, and MIC (minimum inhibitory concentration) using E Test or automated systems such as Vitek.Molecular diagnostic testing, such as polymerasechain reaction or isoelectric focusing, has also been used successfully. However, these tests may be beyond the meansof a typical clinicalmicrobiology laboratory.
The Clinicaland Laboratory StandardsInstitute(CLSI) has developed guidelines for the detection of ESBL-producing organisms.t? Despitethese guidelines, the microbiological diagnosis is still elusive. One problem is that ESBL activity differs by the specific third-generation cephalosporin. Consequently, the choice of testedcephalosporin may impact the ability to detect the enzyme. As an example, an ESBL-producing E. coli may actively hydrolyze ceftazidime, with an associated MIC of 128
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The Annals of Pharmacotherapy • 2007September, Volume 41 • 1429 K YangandBJ Guglielmo jlglrnL; however,there may be a less potent impact on cefotaxime, with an MIC of 4 jlglmL. Thus, depending on the substrate, a given isolate mayor may not be correctly identified as an ESBL-producing isolate. Per the CLSI guidelines, a 2 step screening and confirmatory process should beused.The organism should firstbescreened for reduced susceptibility to anyone of the following substrates: cefotaxime, ceftriaxone, ceftazidime, cefpodoxime, or aztreonam,using either diskdiffusion or brothmicrodilution MIC testing. Considering that the sensitivity of the disk diffusion methodcan varydepending on the substrate, the use of more than 1 of the 5 preferred substrates willimprove the sensitivity of thetest," If the initial screening testis positive, a phenotypicconfirmatorytest is performed using cefotaximeand ceftazidime, aloneand in combination with clavulanic acid, using either disk diffusion or microdilution testing.If using disk diffusion, an increase of 5 mm or rnorein zone size of eithercefotaxime or ceftazidime withthe addition of a clavulanie acidconfirms the presence ofESBLs. Usingmicrodilutiontesting, a decrease of 3 or moredoubling dilutions in the MICof eitherantibiotic is alsoconfirmatory.
If an ESBL is detected, all penicillins, second-and third-generation cephalosporins (excluding the cephamycins), and aztreonarn should bereported as resistant, even if in vitrotest results indicate susceptibility. As described later,thefourth-generation cephalosporin cefepime mayofferin vitroandin vivoutility. The confirmatory testing step,unfortunately, often requires an additional day to perform,potentiallydelaying optimal therapy. Therapeutic decisions based on the initial screening test may lead to overtreatrnent with more broad-spectrum agents.However, awaiting the results of theconfirmatory testmay result in increased morbidity.
Even with the phenotypicconfirmatory test, false-positiveandfalse-negative results occur. Certain strains of E. coli and K.pneumoniae that hyperproduce SHV-l have been associated withMICs to ceftazidime as high as 32 jlglrnL, resulting in a false-positive test. 21 ,22 More importantly, falsenegativeresults also occur with the confirmatory test. One reason for a false-negative result is associated with the inoculum effect. The inoculum effect is typically described as a fourfold increase in the MIC associated with an increase in inoculum size." The cephalosporin MIC has been shown to increaseas the inoculumsize of the ESBLproducingbacteriaincreasesfrom 104-5 to 106-7 cfu/ml.. Particularly worrisome is the observation that the inoculum effect can be observed with inoculum sizes within 0.5 log unitof the standard CLSIinoculum size,a phenomenon likely encountered in routine laboratory testing." When bacteria have been tested for ESBL at the lower range of the CLSI standard inoculum, several strains of E. coliand K.pneumoniae carrying ESBLs of the TEM, SHY,and CTX-M type have been associated withfalse-negative readings. Although thisphenomenon is of concern, morerecentdata suggest that the inoculumeffectassociated with these standard CLSI inoculum sizes is unlikely to beclinically significant,"
False-negative results can also occur when ESBL-producing isolates concomitantly harbor AmpC~-l actamases. In these strains, the AmpC~-l actamase resists inhibition by the clavulanic acid and likely masks the effect of the clavulanic acid on the cephalosporin in the ESBL confirmatory test. 26 This phenomenon is problematic considering that no recommendations exist for detectingESBLs in Enterobacteriaceae other than E. coli, K. pneumoniae, or P. mirabilis. Similarly,there are no CLSI recommendations for the detection of ArnpC~-l actamases.
Between 1998 and 2004, 8.9% of E. coli and 20.3% of K. pneumoniae from the SENTRY Asia-Pacific Surveillance Program were ESBL-positive by initial screening test but negative with the confirmatory test," In this particular investigation, plasmid-borne AmpC~-Iactarnases were observed in 62% of thoseE. coliand 75% of thoseK. pneumoniae with negative confirmatory tests.A false-negative confirmatory test POtentially resultsin erroneously reporting the organism as susceptible to third-generation cephalosporins and subsequent selection of inadequate therapy,"
Detection of AmpC~-Iactarnases is even more difficult thandetection of ESBLs. Organismswith AmpC~-l acta mases may not necessarily conferresistance to broad-spectrum cephalosporins using conventional CLSI break-POints. 26 No screening or confirmatory tests for AmpC detection have been established. In the absence of CLSI guidelines, surrogate markers may be used to inferproductionof plasmid AmpC~-l actarnases in Enterobacteriaceae based on theobservation thatplasmid AmpC-producing isolates are resistant to cephamycins and~-Iactarnase inhibitor COmbinations. 26 Thus,cefoxitin resistance in the presence of resistance to an expanded-spectrum cephalosporin, such as ceftazidime, suggests the presence of AmpC enzymes. Analogously, concomitant resistance to both an expandedspectrum cephalosporin and a~-Iactarnase inhibitorcombination shouldalso raise suspicion for AmpC production. As an example, a ceftazidime-resistant E. coli that is also sensitive to cefoxitin and/orc1avulanic acid is suggestive of EsBL production. However, a ceftazidime-resistant E. coli thatis resistantto either cefoxitin and/orc1avulanic acid is Suspicious for beingan AmpC~-Iactarnase producer. Although these tests are sensitive for determining the presence of AmpC~-l actarnases, neithermethodis specific and results are highlydependent on the bacterial species or the particular~-l actarnase enzyme tested. 26 ,28 In particular, some ESBL-producing organismsmay have elevated lv1ICs to cefoxitinor~-l actaml-Iactarnase inhibitorcombinations. 3 ,l o Independent of the selected screening test, Phenotypic confrrmatory testsare stillrequired.
Treatment Options
As previously noted, the identification of an ESBL-producing organism precludes the use of penicillins, thirdgeneration cephalosporins, and"aztreonam. To date, treatment choices have been based on in vitro susceptibility data and observational studies.Carbapenems, specifically irnipenem and meropenem, must be considered the treatmentof choicedue to theirsuperiorin vitroactivity against EsBL-and AmpC-producing organisms and associated fa-Vorable clinical experience.P" Three studies have evaluated the effectiveness of imipenem compared with ciprofloxacin for the treatment of bacteremia due to an ESBL-producing organism. In a large, prospectivestudy of 455 episodes of K. pneumoniae bacteremia from 12different hospitals in 7 countries, 85 (18.7%) episodes were due to ESBL-producing isolates," Carbapen-em monotherapy was found to be superior to fluoroquinolones and non-carbapenem~-I actarns in the subgroup of ESBL-producers. Treatment with a carbapenem was independentlyassociated with decreasedall-cause 14 day (OR 0.09; CI O.Olto 0.65; P = 0.017) and 28 day (OR 0.28; CI 0.08 to 1.00; P =0.05) mortality by multivariate analysis.
Thisresult wasevenmorepronounced for 14day and28 day mortality attributed to K.pneumoniae bacteremia.
Endimiani et a1?9 evaluated 17 patientswith nonfatal K. pneumoniae bacteremia due to the TEM-52 ESBL susceptible to both imipenem and ciprofloxacin.Eight of 10 patients treated with imipenem experienced a complete responseto therapy. In contrast,2 of 7 patients who received ciprofloxacin achieved a partial response; 5 of 7 patients failed therapy completely. The difference between the 2 treatmentoutcomes was statistically significant (p =0.03), despite the small sample size. In contrast, another study found no difference in 30 day mortality in patients with ESBL-producing E. coli and K. pneumoniae bacteremia when treatedwitheither ciprofloxacin or imipenem,"
Ertapenem is a more recently approved carbapenem with the advantage of once-dailydosing. While ertapenem exhibits predictable activity against ESBL-producing E. coli and K. pneumoniae, it is somewhat less active when compared with imipenemand meropenem. In one in vitro investigation,95% of ESBL-producingE. coli and Klebsiella isolates were determined to be susceptible to ertapenem, compared with 98.8% susceptible to imipenem and 98.2% to meropenem.t'-" Ertapenem-resistant Klebsiella and Enterobacter spp.submitted to a reference laboratory were evaluated for irnipenem and meropenem susceptibility. 36 Eighty-two percent of Klebsiella isolates and68%of Enterobacter isolates weresusceptible to imipenem. Meropenem wasactive against 74%of all isolates tested. Carbapenem resistance was mediated by ESBLs (Klebsiella spp.) and AmpC~-l actarnases (Enterobacter spp.),as well as impermeability dueto lossof outermembrane proteins. At the time of writing, there wereno published reports regarding theclinicalefficacy of ertapenem in the treatment of ESBLs.
Clinical experience treating ESBL-producers using~ lactamase inhibitor combinations, such as piperacillin/ tazobactarn and ticarcillin-clavulanic acid,has been limited to only a few patients. 37 • 40 A retrospective study of an outbreak of K. pneumoniae in 33 neonates examinedthe efficacy of piperacillin/tazobactam compared with other antibacterial agents,including imipenem," Eighteen (54.5%) of the isolates were determined to produce ESBLs. Six (35.3%)of the neonatestreated with irnipenem died compared with the 6 (46.2%) of 13 neonates treated with piperacillin/tazobactam. While these studies suggest that -lactarnase inhibitorcombinations may have a role in the treatmentof ESBL-producers, these agents cannot berecommendedfor the treatmentof serious infections without additional clinical experience. As AmpC-producing organ-.theannals
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Second-and third-generation cephalosporins should be avoided in the treatment of both ESBL-and AmpC-producingbacteriadue to in vitroresistance (ESBL) or the potential for chromosomal resistance (AmpC) by either induction of~-l actamase production or selection of derepressed mutants. Although anecdotal clinical success has been reported with the use of cephalosporins for the treatmentof various infections withESBL-producing Enterobacteriaceae, clinical failures havealsobeenreported, evenwith MICs withinthe susceptible range. 33 ,41,42 Wong-Beringer et al.3 2 evaluated 36 episodes of bloodstream infection with ESBL and AmpC~-l actamase-producing E. coli and K. pneumoniae resistant to ceftazidime. A trendtowardbetter clinical response was observed with non-cephalosporin antibiotics compared with extended-spectrum cephalosporins for both E. coliand K.pneumoniae. Patients receiving thirdgeneration cephalosporins otherthan ceftazidime had better responses compared withthosewho received ceftazidime (7 of 10vs 2 of 6, respectively), although theeffect was notstatistically significant, likely due to smallsample sizes.
Treatment failure with a cephalosporin has also been associated with an MIC greater than or equal to 8 pg/mL compared with organismswith an MIC less than or equal to 2 pglmL.30 Second-and third-generation cephalosporins shouldalso be avoided in the treatment of infections due to AmpC-producing organisms. Poor outcomes have been associated with use of cefotaxime or ceftazidime in the treatment of bacteremia due to AmpC-producing K.pneumoniae and thus shouldbe avoided/ Cefepime, a fourth-generation cephalosporin, has been investigated as an alternative for the treatmentof resistant Enterobacteriaceae because of its increased stability against AmpC~-l actamase.
The SENTRYAntimicrobial Surveil-lanceProgramsurveyed more than 3000 ceftazidirne-resistant gram-negative bacilli between 1998and 2004. 43 Ninety percent of ceftazidime-resistant Enterobacteriaceae were foundto be susceptible to cefepirne. Acinetobacter spp.and P. aeruginosa were infrequently susceptible, at 16.2% and 29.9%, respectively. In contrast, cefepirne was active against 94%of AmpC-producing Enterobacter spp.
The use of cefepime for the treatmentof infections due to ESBL-producing bacteriais controversial.tv" In a comson study" of cefepirne versus imipenem for the treatment of nosocomial pneumonia due to ESBL-producing organisms, cefepime failed in 4 of 13 patients compared with no failures in 10 imipenem-treated patients.K. pneumoniae was isolated in 21 patients, E. aerogenes in 1 patient,and 1 patientwas coinfected with both K. pneumoniae andA. baumannii. Although clinical experience with cefepime is limited, pharmacodynamic data suggest that this drug may have a role in the treatment of ESBL-pro-ducing organisms becauseit exhibitsgreater time over the MIC (T>MIC), the pharmacodynamicprinciple that best correlates with in vivo efficacy for~-l actam antibiotics. Cefepime was found to be superior to piperacillintazobactam at conventional dosingregimens in one study," However,cefepime was found to be most effective when administered at high dosesor as a continuous infusion,"
ESBL-producing organisms oftenexhibit reduced susceptibility to non-B-lactam antibiotics including trirnethoprim/ sulfamethoxazole, aminoglycosides, andfluoroquinolones.s'" Eighteen percent of ESBL-producing K. pneumoniae bacteremic patients werefoundto be ciprofloxacin-resistant in one series.P Spanu et a1. 49 found only 58% of ESBL-producing Enterobacteriaceae to be susceptible to ciprofloxacin; only 56% were susceptible to gentamicin. Even in isolates demonstrating in vitro susceptibility to fluoroquinolones, ciprofloxacin has been observedto be inferior to carbapenems in the treatment of ESBL-producing K. pneumoniae bacterernia.v-'t While fluoroquinolones cannot be recommended in a bacteremicpatient with ESBLproducing organisms, they may be considered in patients with non-life-threatening infections,such as urinary tract infection, if the organism is determined to be susceptible.
A potential option for the treatment of extended spectrum or AmpC-producing~-l actamase is the new broadspectrum glycylcycline, tigecycline. In a study evaluating the activity of tigecycline specifically against ESBLand AmpChyperproducing bacteria, tigecycline was active against 83% of isolates tested," One hundred percent of ESBL-producing E. coliand93% of AmpC-hyperproducing E. coliweresusceptibleto tigecycline; 54% of Klebsiella spp. and 85% of Enterobacter spp. were susceptible to tigecycline. Although tigecycline demonstrates in vitroactivity against A. baumannii, resistance has steadily increased. In one study of 82 multidrug-resistant nosocomial Acinetobacter isolates,only 18 (22%) isolates weredetermined to be tigecycline-susceptible; 95% of strains not susceptible to imipenem alsodemonstrated resistance to tigecycline,"
Clinical failure with tigecycline has been reported,particularly in the treatmentof bloodstream infections, potentially due to therelatively low associated serumdrugconcentrations. S6 ,57Aftermultiple dosing of tigecycline 50 mg every 12 hours,serumconcentrations of only 0.62 ± 0.09pglmL have been documented." Clinical experiencewith tigecy-, clinehas beenlimitedto the few Phase3, randomized, double-blind studies usedto obtainFood and Drug Administration approval. These studies evaluated tigecyclinefor the treatment of skinlskin-structure infection andcomplicated intraabdominal infection. s9 ,601\velve(80%) of 15patients with ESBL-producing E. colior K.pneumoniae intraabdominal infections achieved bacterial eradication; however, 2 patients (l with K. pneumoniae, 1 with M. morganiii experienced clinicalfailure. Of note,thesefailures were associated with development of tigecycline resistance during therapy. Tigecycline may be a viableoptionfor infections in the absence of a concomitant bloodstream infection. However, the increasing incidence of tigecycline-resistantA. baumannii and K. pneumoniae is worrisome, especially in multidrug-resistant strains. Confirmatory MIC testing shouldbe performed prior to tigecycline administration, Particularly in more serious infections.
•
The increasing emergence of multidrug-resistant gramnegative bacteria has led to increasing interest in colistin, a polymyxinantibiotic originally discovered in 1947. Colistin has broad-spectrum activity against P. aeruginosa, Acinetobacter spp.,Klebsiella spp.,and Enterobacter spp., but had fallen out of favor due to its potential for nephro-tOXicity. Colistin has been demonstrated to be activẽ ainst 100%of ESBL-producing E. coli and K. pneumoniae. 61 Although colistin demonstrated a relatively high rateof clinical success for treatment of multidrug-resistant P. aeruginosa and A. baumannii, noneof the reported studies originated from prospective clinical trials,and none in-volVed ESBL-producing E. colior Klebsiellal"
In the case presented above, definitive treatment of an EsBL-producing K. pneumoniae bloodstream infection requires the use of eitherimipenem or meropenem. In institutions witha highprevalence of ESBL-producing organisms, imipenem shouldbe considered in all patients with serious infection due to E. coliand Klebsiella, particularly if the initial susceptibility results suggest an ESBLor AmpC producer.If ESBL and AmpC are ruledout, antibiotics shouldbe de-escalated to themostnarrow-spectrum agent.
Summary
The increaseduse of antibiotics, often inappropriately, has resulted in worldwide spreadof antimicrobial-resistant pathogens. Of these resistantpathogens,those associated with ESBL-and AmpC-mediated resistance pose unique problems for the clinician. Difficulties in accurate diagnosis anddetection by the microbiology lab may delay initiation of appropriate therapy, with the potential for increased morbidity and mortality. Increased diligence in the identificationof ESBL-and AmpC-producing organisms is criticaltowardthe selection of optimal therapy (Table 3 ). Therapeutic options are limited,with the exceptionof imipenem and meropenem (and perhaps ertapenem). Although other agents, such as cefepime, colistin, and tigecycline, offer promise, the associated lack of clinical experience Suggests that they be used only in patients unableto toleratecarbapenems. 
